Zolpidem Activation of Alpha 1-Containing GABAA Receptors Selectively Inhibits High Frequency Action Potential Firing of Cortical Neurons

Effective Perturbations by Phenobarbital on INa, IK(erg), IK(M) and IK(DR) during Pulse Train Stimulation in Neuroblastoma Neuro-2a Cells

Phenobarbital (PHB, Luminal Sodium^®) is a medication of the barbiturate and has long been recognized to be an anticonvulsant and a hypnotic because it can facilitate synaptic inhibition in the central nervous system through acting on the γ-aminobutyric acid (GABA) type A (GABA_A) receptors. However, to what extent PHB could directly perturb the magnitude and gating of different plasmalemmal ionic currents is not thoroughly explored. In neuroblastoma Neuro-2a cells, we found that PHB effectively suppressed the magnitude of voltage-gated Na⁺ current (I_Na) in a concentration-dependent fashion, with an effective IC₅₀ value of 83 µM. The cumulative inhibition of I_Na, evoked by pulse train stimulation, was enhanced by PHB. However, tefluthrin, an activator of I_Na, could attenuate PHB-induced reduction in the decaying time constant of I_Na inhibition evoked by pulse train stimuli. In addition, the erg (ether-à-go-go-related gene)-mediated K⁺ current (I_K(erg)) was also blocked by PHB. The PHB-mediated inhibition on I_K(erg) could not be overcome by flumazenil (GABA antagonist) or chlorotoxin (chloride channel blocker). The PHB reduced the recovery of I_K(erg) by a two-step voltage protocol with a geometrics-based progression, but it increased the decaying rate of I_K(erg), evoked by the envelope-of-tail method. About the M-type K⁺ currents (I_K(M)), PHB caused a reduction of its amplitude, which could not be counteracted by flumazenil or chlorotoxin, and PHB could enhance its cumulative inhibition during pulse train stimulation. Moreover, the magnitude of delayed-rectifier K⁺ current (I_K(DR)) was inhibited by PHB, while the cumulative inhibition of I_K(DR) during 10 s of repetitive stimulation was enhanced. Multiple ionic currents during pulse train stimulation were subject to PHB, and neither GABA antagonist nor chloride channel blocker could counteract these PHB-induced reductions. It suggests that these actions might conceivably participate in different functional activities of excitable cells and be independent of GABA_A receptors.

Crosstalk Between GABAergic Neurotransmission and Inflammatory Cascades in the Post-ischemic Brain: Relevance for Stroke Recovery

Adaptive plasticity processes are required involving neurons as well as non-neuronal cells to recover lost brain functions after an ischemic stroke. Recent studies show that gamma-Aminobutyric acid (GABA) has profound effects on glial and immune cell functions in addition to its inhibitory actions on neuronal circuits in the post-ischemic brain. Here, we provide an overview of how GABAergic neurotransmission changes during the first weeks after stroke and how GABA affects functions of astroglial and microglial cells as well as peripheral immune cell populations accumulating in the ischemic territory and brain regions remote to the lesion. Moreover, we will summarize recent studies providing data on the immunomodulatory actions of GABA of relevance for stroke recovery. Interestingly, the activation of GABA receptors on immune cells exerts a downregulation of detrimental anti-inflammatory cascades. Conversely, we will discuss studies addressing how specific inflammatory cascades affect GABAergic neurotransmission on the level of GABA receptor composition, GABA synthesis, and release. In particular, the chemokines CXCR4 and CX3CR1 pathways have been demonstrated to modulate receptor composition and synthesis. Together, the actual view on the interactions between GABAergic neurotransmission and inflammatory cascades points towards a specific crosstalk in the post-ischemic brain. Similar to what has been shown in experimental models, specific therapeutic modulation of GABAergic neurotransmission and inflammatory pathways may synergistically promote neuronal plasticity to enhance stroke recovery.

Midazolam at low nanomolar concentrations affects long-term potentiation and synaptic transmission predominantly via the α1-GABAA receptor subunit in mice

BACKGROUND

Midazolam amplifies synaptic inhibition via different GABAA receptor subtypes defined by the presence of α1, α2, α3 or α5-subunits in the channel complex. Midazolam blocks long-term potentiation and produces postoperative amnesia. The aims of this study were to identify the GABAA receptor subtypes targeted by midazolam responsible for affecting CA1-long-term potentiation and synaptic inhibition in neocortical neurons.

METHODS

The effects of midazolam on hippocampal CA1-long-term potentiation were studied in acutely prepared brain slices of male and female mice. Positive allosteric modulation on GABAA receptor-mediated miniature inhibitory postsynaptic currents was investigated in organotypic slice cultures of the mouse neocortex. In both experiments, wild-type mice and GABAA receptor knock-in mouse lines were compared in which α1-, α5-, α1/2/3-, α1/3/5- and α2/3/5-GABAA receptor subtypes had been rendered benzodiazepine-insensitive.

RESULTS

Midazolam 10nM completely blocked long-term potentiation (midazolam mean±SD 98±11%, n=14/8 (slices/mice) vs. control 156±19%, n=20/12; p<0.001). Experiments in slices of α1-, α5-, α1/2/3-, α1/3/5- and α2/3/5-knock-in mice revealed a dominant role for the α1-GABAA receptor subtype in the long-term potentiation suppressing effect.In slices from wild-type mice, midazolam increased (mean±SD) charge transfer of miniature synaptic events concentration-dependently, 50nM: 172±71% (n=10/6) vs. 500nM: 236±54% (n=6/6), p=0.041. In α2/3/5-knock-in mice, charge transfer of miniature synaptic events did not further enhance when applying 500nM midazolam, 50nM: 171±62% (n=8/6) vs. 500nM: 175±62% (n=6/6), p=0.454) indicating two different binding affinities for midazolam to α2/3/5- and α1-subunits.

CONCLUSIONS

These results demonstrate a predominant role of α1-GABAA receptors in the actions of midazolam at low nanomolar concentrations. At higher concentrations, midazolam also enhances other GABAA receptor subtypes. α1-GABAA receptors may already contribute at sedative doses to the phenomenon of postoperative amnesia that has been reported after midazolam administration.

Regulation of GABAARs by Transmembrane Accessory Proteins

The vast majority of fast inhibitory transmission in the brain is mediated by GABA acting on GABAA receptors (GABAARs), which provides inhibitory balance to excitatory drive and controls neuronal output. GABAARs are also effectively targeted by clinically important drugs for treatment in a number of neurological disorders. It has long been hypothesized that function and pharmacology of GABAARs are determined by the channel pore-forming subunits. However, recent studies have provided new dimensions in studying GABAARs due to several transmembrane proteins that interact with GABAARs and modulate their trafficking and function. In this review, we summarize recent findings on these novel GABAAR transmembrane regulators and highlight a potential avenue to develop new GABAAR psychopharmacology by targeting these receptor-associated membrane proteins.